On Tuesday, Humacyte Inc (NASDAQ: HUMA) opened lower -8.11% from the last session, before settling in for the closing price of $1.11. Price fluctuations for HUMA have ranged from $0.91 to $4.85 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 42.43%. Company’s average yearly earnings per share was noted 76.74% at the time writing. With a float of $163.95 million, this company’s outstanding shares have now reached $193.00 million.
Humacyte Inc (HUMA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Humacyte Inc is 15.05%, while institutional ownership is 23.95%. The most recent insider transaction that took place on Aug 19 ’25, was worth 1,793,000. In this transaction Director of this company sold 1,100,000 shares at a rate of $1.63, taking the stock ownership to the 591,685 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Director sold 549,360 for $1.83, making the entire transaction worth $1,005,329. This insider now owns 1,691,685 shares in total.
Humacyte Inc (HUMA) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.21 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.25) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 76.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 51.26% during the next five years compared to 42.43% growth over the previous five years of trading.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Check out the current performance indicators for Humacyte Inc (HUMA). In the past quarter, the stock posted a quick ratio of 0.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 125.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.24, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.45 in one year’s time.
